Metastatic bone disease: Developing strategies to optimize management

American Journal of Cancer

Volumn 2, Issue 4, 2003, Pages 269-281

  Brown, Janet E ^a   Coleman, Robert E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMGN 0007; ANALGESIC AGENT; ANASTROZOLE; ANTICONVULSIVE AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; ETHYLENEDIAMINE TETRAKIS(METHYLENEPHOSPHONIC ACID); ETIDRONIC ACID; EXEMESTANE; FENTANYL; FLUOROPYRIMIDINE; IBANDRONIC ACID; LETROZOLE; MEGESTROL ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OSTEOPROTEGERIN; PACLITAXEL; PAMIDRONIC ACID; PROSTATE SPECIFIC ANTIGEN; SAMARIUM 153; STRONTIUM 89; TAXANE DERIVATIVE; TRASTUZUMAB; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR MARKER; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ADVANCED CANCER; APOPTOSIS; BONE METASTASIS; BONE PAIN; BONE RADIOGRAPHY; BONE SCINTISCANNING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLLAGEN DEGRADATION; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG CHOICE; DRUG POTENCY; DYSPEPSIA; FEVER; HUMAN; HYPERCALCEMIA; IMAGE ANALYSIS; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; SPINAL CORD COMPRESSION; STEM CELL; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; VOMITING;

EID: 0041357032     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200302040-00005     Document Type: Review

References (68)

1. Schottenfeld D, Fraumeni JF, editors. Cancer epidermiology and prevention. 2nd ed. New York: Oxford University Press, 1996
2. DeVita VT, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology. Philadelphia (PA): Williams and Wilkins, 2001
3. Coleman RE. Skeletal complications of malignancy. Cancer 1998; 80: 1588-94
4. MacVicar D. Radiology and magnetic resonance imaging. In: Rubens RD, Mundy GR, editors. Cancer and the skeleton. London: Martin Dunitz, 2000: 113-36
5. Lipton A, Costa L, Ali S, et al. Use of bone turnover formonitoring bone metastases and the response to therapy. Semin Oncol 2001; 4 Suppl. 11: 54-9
6. Lipton A, Theriault RL, Hortobagyi GH, et al. Pimidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases; long-term follow up of two randomised, placebo controlled trials. Cancer 2000; 88: 1082-90
7. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma, Myeloma Aredia Study Group. N Engl J Med 1996; 334: 488-93
8. Saad F, Gleason D, Murray R, et al. A randomised, placebo controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68
9. Rosen L, Gordon D, Tchekmedyian S, et al. Zometa significantly increases the median time to first skeletal related event (SRE) in patients with osteolytic bone metastases from non-small cell lung cancer (NSCLC) and other solid tumours (OST) [abstract]. Lung Cancer 2001; 34 Suppl. 1: 67
10. Pantel K, Core RJ, Fostad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999; 91: 1113-24
11. Orr FW, Lee J, Duivenvoorden WCM, et al. Pathophysiologic interactions in skeletal metastases. Cancer Suppl 2000; 88: 2912-8
12. Mundy GR. Mechanisms of bone metastasis. Cancer 1997; 80 Suppl. 8: 1546-56
13. Kanis JA, McCloskey EV. Bone turnover and biochemical markers in malignancy. Cancer 1997; 80 Suppl. 8: 1538-45
14. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4: 30-4
15. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-87
16. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology: International Bone and Cancer Study Group. J Clin Oncol 1998; 16: 3890-9
17. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomised, controlled clinical trials. J Clin Oncol 2001; 19: 558-67
18. Coleman RE. Management of bone metastases. Oncologist 2000; 5: 463-70
19. Body JJ, Lichinitser MR, Diel IE, et al. Double-blind placebo controlled trial of ibandronate in breast cancer metastatic to bone [abstract 2222]. Proc Am Soc Clin Oncol 1999; 18: 575a
20. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal events in patients with osteolytic metastases. Cancer 2001; 91: 1191-200
21. Diel IJ, Marschner M, Kindler O, et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases [abstract 488]. Proc Am Soc Clin Oncol 1999; 18: 128a
22. Jagdev SP, Purohit OP, Heatley S, et al. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 2001; 12: 1433-8
23. Van Holten-Verzantvoort AT, Bijvoet OLM, Cleton FJ, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonate (APD) treatment. Lancet 1987; II: 983-5
24. Paterson AHG, Powles TJ, Kanis, JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65
25. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases treated with intravenous pamidronate: results from a multicentre randomised controlled trial. J Clin Oncol 1996; 14: 2552-9
26. Hortobagyi GN, Theriault RL, Porter L. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New Engl J Med 1996; 335: 1785-91
27. Hultborn R, Ryden S, Gunderson S, et al. Efficacy of pamidronate on skeletal complications from breast cancer metastases: a randomised prospective double blind placebo controlled trial. Acta Oncologica 1996; 35 Suppl. 5: 73-4
28. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advance breast cancer and lytic bone lesions: a randomised, placebo-controlled trial. J Clin Oncol 1999; 17: 846-54
29. Lahtinen R, Laasko M, Palva I, et al. Randomised placebo controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049-52
30. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998; 16: 593-602
31. McCloskey EV, MacLennan ICM, Drayson MT, et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998; 100: 317-25
32. Dearnaley DP, Sydes MR, on behalf of the MRC PR05 collaborators. Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC PR05 trial [abstract 693]. Proc Am Soc Clin Oncol 2001; 20: 174a
33. Lipton A, Costa L, Ali SM, et al. Bone markers in the management of metastatic bone disease. Cancer Treat Rev 2001; 27: 181-5
34. Paterson AHG, Powles TJ, Kanis J, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1998; 11: 59-65
35. Hortobagyi GN, Thierault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications on patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785-91
36. Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Available in: The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2002
37. National Institutes of Health Concensus Development Conference Statement. Adjuvant therapy for breast cancer. 2000 Nov 1-3. J Natl Cancer Inst Monogr 2001; 30: 5-15
38. Bolla M, Gonzalez D, Wardle P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300
39. Goldhirsch A, Gelber RD, Price KN, et al. Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 1994; 343: 377-81
40. Jagdev SP, Coleman RE, Shipman CM, et al. The bisphosphonate zoledronic acid induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 1126-34
41. Shipman CM, Rogers MJ, Apperley JF, et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997; 98: 665-72
42. Shipman CM, Croucher PI, Russell RG, et al. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998; 58: 5294-7
43. Powles TJ, Paterson AHG, Nevantaus A, et al. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer [abstract]. 34th Proc Am Soc Clin Oncol 1998; 17: 123a
44. Diel IJ, Solomayer E, Gollan C, et al. Bisphosphonates in the reduction of metastases in breast cancer: results of the extended follow-up of the first study population [abstract 314]. Proc Am Soc Clin Oncol 2000; 19: 82a
45. Saarto T, Blomqvist C, Virkkunen P, et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5 year results of randomised controlled trial. J Clin Oncol 2001; 19: 10-7
46. Smith MR, McGovern FR, Zeitman AI, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-54
47. Saarto T, Blomquist C, Valimaki M, et al. Chemical castration induced by adjuvant cyclophosphamide, methotraxate and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997; 15: 1341-7
48. Hillner BE, Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease. Semin Oncol 2001; 28 Suppl. 11: 64-8
49. McCloskey E, Guest JF, Kanis JA. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs 2001; 61: 1253-74
50. Honore P, Luger NM, Sabino AC, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction: skeletal pain and pain-related neurochemical reorganisation of the spinal cord. Nat Med 2000; 6: 521-8
51. Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007: a recombinant osteoprotogerin construct in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97: 887-92
52. Mirrels H. Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathological fracture. Clin Orthop 1989; 249: 256-64
53. Hardman PDJ, Robb JE, Kerr GR, et al. The value of internal fixation and radiotherapy in the management of upper and lower limb bone metastases. Clin Oncol 1992; 4: 244-8
54. Janjan NA. Radiation for bone metastases: conventional techniques and the role of systemic radiopharmaceuticals. Cancer 2000; 89: 363-8
55. Houston SJ. Clinical use of radioisotopes for bone metastases. In Rubens RD, Mundy GR, editors. Cancer and the Skeleton. London: Martin Dunitz, 2000: 172-82
56. Janjan N. Bone Metastases: approaches to management. Semin Oncol 2001; 28: 28-34
57. Portnow J, Grossman SA. Pain: mechanisms, assessment and management. In: Rubens RD, Mundy GR, editors. Cancer and the skeleton. London: Martin Dunitz, 2000: 183-99
58. Edelstyn GA, Gillespie PJ, Grebbel FS. The radiological demonstration of osseus metastases: experimental observations. Clin Radiol 1967; 18: 158-62
59. Howell A, Mackintosh J, Jones M, et al. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer 1988; 24A: 1567-72
60. Robertson JFR, Jaeger W, Syzmendera JJ, et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. Eur J Cancer 1999; 35: 47-53
61. Berruti A, Torta M, Piovesan A, et al. Biochemical picture of bone metabolism in breast cancer patients with bone metastases. Anticancer Res 1995; 15: 2871-6
62. Costa L, Demers LM, Gouveia A, et al. Biochemical markers of bone turnover correlate with the extent of metastatic bone disease [abstract 2375]. Proc Am Soc Clin Oncol 1999; 18: 615a
63. Ali SM, Demers LM, Leitzel K, et al. Elevated serum N-telopeptide predicts poor prognosis in breats cancer patients with bone metastases [abstract 2549]. Proc Am Soc Clin Oncol 2000; 19: 646a
64. Walls J, Assiri A, Howell A, et al. Measurement of urinary collagen crosslinks indicate response to therapy in patients with breast cancer and bone metastases. Br J Cancer 1999; 80: 1265-70
65. Vinholes JJF, Purohit OP, Abbey ME, et al. Relationships between biochemical and symptomatic response in a double blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997; 8: 1243-50
66. Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998; 34: 2021-6
67. Brown JE, Ellis S, Gutcher S, et al. The bone resorption marker Ntx is strongly correlated with skeletal events in metastatic bone disease and is influenced by dose escalation of clodronate [abstract 1537]. Proc Am Soc Clin Oncol 2002; 21: 385a
68. Coleman RE, Rosen LS, Gordon D, et al. Zoledronic acid (4mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90mg) in patients with breast cancer and bone metastasis [abstract 355]. Breast Cancer Res Treat 2002; 76 Suppl. 1: S95